Assessing the Comparative Efficacy and Safety of Warfarin and Rivaroxaban for Cancer Associated Thrombosis: Experience From a Resource Limited Setting
Cancer Reports · 2025
DOI: 10.1002/cnr2.70105 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cancer Reports, 2025. Verfasst von Abel Tenaw Tasamma und 16 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine; College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia. Hauptthemen laut MEDLINE: Rivaroxaban, Warfarin, Neoplasms, Anticoagulants. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Thromboembolic events are a common cause of morbidity and mortality in patients with cancer. While direct‐acting oral anticoagulants (DOACs) have been established as the preferred agents of anticoagulation in most patients with cancer, data in resource‐limited settings is limited.
Aims
The study aims to assess the comparative efficacy and safety of warfarin and rivaroxaban for cancer‐associated thrombosis (CAT) in a resource‐limited setting. Methods and results A single‐center retrospective cohort study was conducted on 201 patients who were on follow‐up from September 2021 to August 2023. The patients were categorized into two groups (1) warfarin and (2) rivaroxaban. They were then retrospectively followed for 12 months. The primary endpoint was a composite of recurrence of venous thromboembolism (VTE), major bleeding event, or all‐cause mortality. The Cox regression model was used to compare the outcome of the two groups. The baseline mean (standard deviation) age of the patients was 48.4 (15.0) and 140 (69.7%) of them were female. 41.3% of the participants had one or more comorbidities, and the most common types of cancer were gynecologic (28.9%), hematologic (21.4%), and intra‐abdominal (16.9%). The most common type of thrombosis was deep vein thrombosis (DVT) (77.1%). The primary composite outcome of VTE recurrence, major bleeding event, and all‐cause mortality occurred in 25 (24.3%) patients in the warfarin group and 11 (11.2%) in the rivaroxaban group (hazard ratio (HR), 0.48; 95% confidence interval (CI), 0.24–0.97; p = 0.041).
Conclusion
Rivaroxaban was found to be more efficacious and safer than warfarin for patients with CAT in a resource‐limited setting. This finding is congruent with reports from resource‐abundant countries and recommendations from major international societies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine; College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
- John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, USA.
ORCID-Profile: Abel Tenaw Tasamma, Tsegab Alemayehu Bukate, Amanuel Kassu Asefa
Zitieren
APA
Tasamma, A. T., Bukate, T. A., Mehadi, A., Handiso, B. T., Kassa, B. Y., Hassen, E. O., Ayalew, Z. S., Tegegne, D. H., Azibte, G. T., Zewdie, T. A., Shihur, T. Z., Geremamo, Y. D., Mesfin, Y. D., Alemayehu, R. M., Asefa, A. K., Abdela, F., & Melkie, A. (2025). Assessing the Comparative Efficacy and Safety of Warfarin and Rivaroxaban for Cancer Associated Thrombosis: Experience From a Resource Limited Setting. Cancer Reports. https://doi.org/10.1002/cnr2.70105
Vancouver
Tasamma AT, Bukate TA, Mehadi A, Handiso BT, Kassa BY, Hassen EO, et al. Assessing the Comparative Efficacy and Safety of Warfarin and Rivaroxaban for Cancer Associated Thrombosis: Experience From a Resource Limited Setting. Cancer Reports. 2025. doi:10.1002/cnr2.70105
BibTeX
@article{Tasamma2025,
author = {Tasamma, Abel Tenaw and Bukate, Tsegab Alemayehu and Mehadi, Abdulrahim and Handiso, Bereket Tagesse and Kassa, Beniam Yohannes and Hassen, Eman Omer and Ayalew, Zekarias Seifu and Tegegne, Dawit Habtie and Azibte, Gebeyehu Tessema and Zewdie, Tigest Abebaw and Shihur, Tinsaye Zergaw and Geremamo, Yonas Degelo and Mesfin, Yeabsira Dessalegne and Alemayehu, Rediet M and Asefa, Amanuel Kassu and Abdela, Fozia and Melkie, Addisu},
title = {Assessing the Comparative Efficacy and Safety of Warfarin and Rivaroxaban for Cancer Associated Thrombosis: Experience From a Resource Limited Setting},
journal = {Cancer Reports},
year = {2025},
doi = {10.1002/cnr2.70105}
}
EUVIMED